Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Guidelines and recommendations for ADHD in children and adolescents. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Evidence-based recommendations support the use of stimulants as first-line therapy and the consideration of symptom profile in the use of long- or short-acting formulations when treating children and adolescents with severe ADHD.
The drug payment information presented in this summary report reveals substantial use of health care budgets to reimburse long-acting formulations. In 2010, expenditures on long-acting medications had exceeded $35 million (or 77% of total expenditures on ADHD medications) by public drug plans in Canada. Indexing Status Subject indexing assigned by CRD MeSH Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Practice Guidelines as Topics Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: htainfo@cadth.ca AccessionNumber 32012000031 Date abstract record published 12/06/2012 |